Search the Newsreel

Why Is Smith & Nephew (LSE:SN) Facing Fresh Market Attention?

Smith & Nephew Lowers Sales Growth Forecast Following Softer Second Quarter

Smith & Nephew has reduced its full-year revenue growth forecast after a weaker-than-expected second quarter, impacted by lower U.S. knee implant sales and changes in wound care reimbursement rules. Despite this, the company maintained its profit growth and free cash flow guidance due to …

Smith & Nephew cuts sales outlook after weak US trading

Smith & Nephew has lowered its full-year revenue growth forecast to approximately 4% due to weaker-than-anticipated performance in its US orthopaedics and wound care businesses during the second quarter. Despite this, the company maintained its guidance for trading profit, free cash flow, and return …

UK's Smith+Nephew cuts 2026 revenue view on weak US knee implant demand

UK Stock Market News: SEGRO, Smith & Nephew, AG Barr

Smith & Nephew SNATS (NYSE:SNN) Trading Down 5.8% on Disappointing Earnings

Smith & Nephew plc 2026 Q2 - Results - Earnings Call Presentation (NYSE:SNN) 2026-08-04

Smith & Nephew H1 Profit Rises

(RTTNews) - Smith & Nephew Plc (SNN, SN.L) reported that its first half profit before tax totaled $380 million compared to $362 million, a year ago. For the half year ended June 27, 2026, attributable profit was $303 million compared to $293 million in …

Smith & Nephew (NYSE: SNN) details 839.9M voting shares and treasury stock

Smith & Nephew plc has updated its voting share capital as of July 31, 2026, comprising 839,857,161 ordinary shares with voting rights. This figure excludes 37,876,589 treasury shares from its total issued share capital of 877,733,750 shares. Shareholders are instructed to use the voting …

Smith & Nephew (SNN) Falls 2.38% to $31.56 as Support Level Comes into Focus - Point of Control

Nephros Inc (NEPH) Financial Health: Profitability & Balance Sheet Analysis

The article provides an analysis of Nephros Inc's (NEPH) financial health, noting its current financial score of 6.42, ranking 125 out of 159 in its industry. The company's financial status is described as robust, with low operating efficiency, and it recently reported a 6.87% …

Nano Dimension and 4 More Stocks See Action From Activist Investors

Activists also report to the SEC on Smith & Nephew, Navigator Holdings, Global Net Lease, and Radcom. Continue Reading

Nephros Inc (NEPH) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Nephros Inc (NEPH), detailing its current valuation score, P/E ratio, and market data. It highlights that the company's valuation score is 8.25, placing it 75th in its industry, and notes its P/E ratio of 46.43. The analysis …

Smith & Nephew Expands Wound Care Portfolio in $22B Market

Smith & Nephew (SNN) is expanding its wound care portfolio and addressing the chronic wound management market, which is projected to grow to over $30 billion by 2030. The company recently launched two new innovations, ALLEVYN COMPLETE CARE Foam Dressing and RENASYS EDGE Negative …

Nephros Inc (NEPH) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Nephros Inc (NEPH), detailing its current price momentum score, identified support and resistance levels, and a summary of technical indicators and moving averages. According to the analysis, the stock is currently trading between $3.66 (resistance) and $3.01 …

Smith & Nephew PLC (SNN) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Smith & Nephew PLC (SNN), highlighting its current valuation score and P/E ratio. The company's valuation score is 5.83, ranking it 190 out of 199 in the Healthcare Equipment & Supplies industry. While the P/E ratio is …

Are Smith & Nephew (LSE:SN) And Convatec (LSE:CTEC) Defining The UK Healthcare Stocks Story?

Smith+Nephew’s TESSA™ Spatial Surgery System granted De Novo classification by the FDA sparking a generational leap in Sports Medicine for personalized planning and procedural innovation

Smith+Nephew has received De Novo classification from the FDA for its TESSA Spatial Surgery System, marking a significant advancement in Sports Medicine. The system utilizes AI, augmented reality, and advanced imaging for personalized planning and real-time navigation during arthroscopic procedures, initially focusing on femoral …

Smith+Nephew's AI system overlays a 3D bone model in ACL surgery

Smith+Nephew has received FDA De Novo classification for its TESSA Spatial Surgery System, marking a new category for intra-articular orthopedic stereotaxic navigation instruments. The TESSA system uses AI and cloud-based deep learning algorithms to create patient-specific 3D anatomical models from pre-operative scans, which are …

Smith & Nephew agrees to settle ERISA class action with cash payments to plan participants

Smith & Nephew has agreed to a $350,000 settlement in an ERISA class action lawsuit, addressing allegations of excessive managed account service fees in its U.S. savings plan. Participants and beneficiaries from August 30, 2018, to May 13, 2026, are eligible for pro rata …

Smith & Nephew Number of Employees 2026 | Employee Count & Headcount Data

As of March 2026, Smith & Nephew plc has approximately 18,547 employees worldwide, marking a 1.3% decline since 2023 but a recovery from a low in 2025 Q1. The company is actively hiring with 1,218 active job postings in 2026, a 44.1% increase from …

Smith & Nephew PLC (SNN) Stock Up 4.6% but GF Value Says Overvalued -- GF Score: 84/100

Smith & Nephew PLC (SNN) saw its stock rise by 4.6% to $32.56, but GuruFocus's GF Value indicates it is 1.4% overvalued compared to its intrinsic value of $32.11. Despite this, SNN holds a strong GF Score of 84/100, driven by high profitability and …

Cevian Capital Lifts Smith & Nephew Stake Above 14% in Late-July Disclosure

Smith & Nephew SNATS (SNN) to Announce Quarterly Earnings on Tuesday

Form 13D/A Smith & Nephew plc For: 27 July By Investing.com

This article announces the filing of Form 13D/A for Smith & Nephew plc on July 27th. Form 13D/A is an amendment to a Schedule 13D, which is filed with the SEC when a beneficial owner acquires more than 5% of a company's stock, indicating …

Cevian Capital reports 14.18% Smith & Nephew stake (NYSE: SNN)

Cevian Capital II GP Limited has reported a beneficial ownership of 119,179,419 ordinary shares in Smith & Nephew plc, representing 14.18% of the company's outstanding shares. The investment, totaling approximately $1.67 billion, was funded from Cevian Funds' general working capital, with sole voting and …

Nephros Inc (NEPH) Institutional Confidence

Nephros Inc (NEPH) has an institutional shareholding score of 5.00, placing it 96th out of 160 in its industry. The institutional shareholding proportion has increased by 6.10% quarter-over-quarter to 50.96%. James Simons is the largest institutional shareholder, holding 0.92% of outstanding shares.

Nephros Inc (NEPH) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey addresses the revenue breakdown for Nephros Inc (NEPH), detailing business segments, regional revenue, and profit contribution. It states that the relevant financial data for these categories have not yet been disclosed by the company. The page provides a general overview …

Are Smith & Nephew (LSE:SN) And Hikma Pharmaceuticals (LSE:HIK) Shaping Today's Healthcare Stocks Debate?

Smith & Nephew (NYSE: SNN) shows Cevian at 14.010786% voting stake

Smith & Nephew (NYSE: SNN) reported a significant change in major shareholding, with Cevian Capital II G.P. Limited now holding 14.010786% of voting rights, up from 13.206621%. This holding, totaling 117,912,733 voting rights, is primarily through Cevian Capital II Master Fund L.P. and Cevian …

Smith & Nephew stock holds steady on 2025 revenue and margin gains

Smith & Nephew's stock is supported by strong 2025 financial results, with revenue reaching $5.81 billion and an adjusted operating profit margin of 17.3%. The company demonstrated robust underlying revenue growth and significant margin improvement, indicating its ability to absorb pricing pressures and product-mix …

Smith & Nephew (SNN) Gains 1.59% as Stock Tests Key Resistance Near $32.60 - Ichimoku Cloud

Nephros Inc (NEPH) Dividends & Stock Splits: Historical Payouts and Event Timeline

The article provides an overview of Nephros Inc (NEPH) dividends and stock splits. It states that no dividends have been distributed over the past five years. Key financial data like market cap and P/E ratio are also presented.

Nephros Inc. (NEPH) Retreats 3.45% as Stock Tests Key Support Zone - ATR Trailing Stop

Smith & Nephew plc Revenue Breakdown – LSE:SN.

NEPH Q1 2026 Earnings: EPS Slightly Misses Estimates, Stock Declines - Financial Summary